Amyloidosis
MONDO:0019065A disorder characterized by the localized or diffuse accumulation of amyloid protein in various anatomic sites. It may be primary, due to clonal plasma cell proliferations; secondary, due to long standing infections, chronic inflammatory disorders, or malignancies; or familial. It may affect the nerves, skin, tongue, joints, heart, liver, spleen, kidneys and adrenal glands.
Also known as: amyloid, amyloid disease, amyloidoses, amyloidosis, amyloidosis (disease)
322 clinical trials for this condition and its sub-types, 133 tagged with Amyloidosis itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Amyloidosis
-
AL amyloidosis 92 trials · 98 incl. sub-types
2 sub-types
- Primary systemic amyloidosis 22 trials
- Primary localized amyloidosis 0 trials
-
Wild type ATTR amyloidosis 95 trials
-
Hereditary amyloidosis 19 trials · 79 incl. sub-types
9 sub-types
- Familial amyloid neuropathy 52 trials · 54 incl. sub-types Sub-types →
- Cerebral amyloid angiopathy 16 trials · 17 incl. sub-types Sub-types →
- APP-related brain and vascular amyloidosis 0 trials · 5 incl. sub-types Sub-types →
- Familial primary localized cutaneous amyloidosis 1 trial Sub-types →
- Finnish type amyloidosis 0 trials
- ITM2B amyloidosis 0 trials Sub-types →
- Familial visceral amyloidosis 0 trials Sub-types →
- Pulmonary amyloidosis 0 trials
- Variant ABeta2M amyloidosis 0 trials
-
ABeta2M amyloidosis 0 trials · 34 incl. sub-types
2 sub-types
- Wild type ABeta2M amyloidosis 34 trials
- Variant ABeta2M amyloidosis 0 trials
-
Primary cutaneous amyloidosis 4 trials · 5 incl. sub-types
5 sub-types
- Lichen amyloidosis 2 trials
- Familial primary localized cutaneous amyloidosis 1 trial Sub-types →
- Macular amyloidosis 1 trial
- Amyloidosis cutis dyschromia 0 trials
- Nodular cutaneous amyloidosis 0 trials
-
AA amyloidosis 2 trials
-
Soft tissue amyloid neoplasm 1 trial
-
AApoAIV amyloidosis 0 trials
-
AH amyloidosis 0 trials
-
ALECT2 amyloidosis 0 trials
-
Amyloidosis bronchopulmonary 0 trials
-
Immunoglobulin heavy-and-light chain 0 trials
Most studied deeper sub-types
-
Heart scan tracer may reveal Chemo's effect on amyloid buildup
Disease control Stopped earlyThis pilot study tests whether a special PET scan tracer called 18F florbetapir can detect changes in amyloid protein deposits in the heart of people with AL cardiac amyloidosis who are receiving chemotherapy. Four participants will have a PET/CT scan before starting chemotherapy…
Phase 4 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Experimental drug aims to stop rare heart disease in its tracks
Disease control Stopped earlyThis study tested a drug called inotersen in 31 people with a rare condition where a faulty protein builds up in the heart, causing damage. The drug is designed to lower levels of that protein. The trial was stopped early, so it's unclear if it works, but researchers hoped to see…
Phase 2 • Sponsor: Brigham and Women's Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Experimental antibody trial for rare heart disease halted early
Disease control Stopped earlyThis phase 3 study tested an experimental drug called birtamimab in 208 people with advanced AL amyloidosis, a rare disease where abnormal proteins damage organs like the heart. Participants received either birtamimab or a placebo, plus standard chemotherapy. The goal was to see …
Phase 3 • Sponsor: Prothena Biosciences Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Promising drug combo for rare amyloidosis hits snag: trial ends early
Disease control Stopped earlyThis study tested a drug called ixazomib plus dexamethasone against other standard treatments for people with relapsed AL amyloidosis, a rare disease where abnormal proteins build up in organs. The trial aimed to see if the combination improved blood markers and slowed heart or k…
Phase 3 • Sponsor: Millennium Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 26, 2026 13:13 UTC